A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

Inclusion criteria

• Histologically diagnosis of local advanced or metastatic breast cancer
• Women must be postmenopausal, or pre-/peri-menopausal women must be on ovarian suppression
• At least 1 line of endocrine therapy in the metastatic or advanced setting
• ECOG performance status score: 0-1;
• Adequate organ functions as defined
• Ability to understand and voluntarily agrees to participate by giving written informed consent for the study.

Exclusion criteria

• the investigators judged that it was not suitable to endocrine therapy
• patients with active brain metastasis (without medical control or with clinical symptoms),
• History of clinically significant cardiovascular or cerebrovascular diseases
• The subject has one of many factors affecting oral 、absorption, distribution, metabolism and excretion of drugs
• Active autoimmune diseases, History of immunodeficiency, including positive HIV serum test result and other acquired or congenital immunodeficiency diseases, or history of organ transplantation
• Have received other similar drugs in the past;
• Known history of allergy to HRS-1358 ingredients